Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma

Authors :: Joseph R. Mikhael
Lotfi Benboubker
Jeremy A. Ross
Shaji Kumar
Paulo Maciag
Ming Zhu
Brigitte Pegourie
Cristina Gasparetto
Philippe Moreau
Joel D. Leverson
Jonathan L. Kaufman
Ravi Vij
Suresh Agarwal
Maria Verdugo
Stefanie Alzate
Susan Diehl
Martin Dunbar
Cyrille Touzeau
Thierry Facon
Martine Amiot
Source :: Journal of Clinical Oncology. 34:8032-8032
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 8032Background: The anti-apoptotic protein BCL-2 has been implicated in the survival of multiple myeloma (MM) cells. Venetoclax (VEN) is an oral, highly selective BCL-2 inhibitor, which induces cel...

Subjects :: Cancer Research
business.industry
Venetoclax
Highly selective
medicine.disease
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Oncology
chemistry
030220 oncology & carcinogenesis
Relapsed refractory
Ven
Cancer research
Medicine
business
Multiple myeloma
030215 immunology

Tools